All Episodes

February 3, 2023

We are kicking off Rare Disease Month by talking about Wilson’s disease, a rare, inherited disorder that causes copper to accumulate in the liver, brain, and other vital organs. It is inherited in an autosomal recessive pattern and left untreated, Wilson’s disease can be fatal. Joining us for this episode is Naseem Amin, the CEO of Orphalan, which develops and commercializes treatments for orphan/rare diseases. In this episode we are exploring Wilson’s disease and the FDA-approved treatment, Cuvrior. 


Naseem Amin (he/him) joined Orphalan in 2017 bringing thirty years of international industry experience in Research and Development, Corporate and Business Development, Venture Capital and Marketing. Naseem previously served as Executive Chairman at Arix Bioscience Plc, listed on the LSE, Venture Partner at Advent Life Sciences, Chief Scientific Officer at Smith and Nephew, where he oversaw corporate R&D, divisional manufacturing, QA/QC and product development functions. Prior to Smith and Nephew, Naseem led the business development functions at both Biogen and Genzyme Therapeutics. For both companies, he initiated and executed a number of transformative acquisitions and transactions.

Naseem has also led the clinical development of five currently marketed therapeutic products. He started his career at Baxter Healthcare where he had executive roles in marketing, product development and clinical research. In addition to his role at Orphalan, Naseem currently serves as a board member and advisor to several not for profit organizations, and a publicly listed biotechnology company listed on the NASDAQ. Naseem is a qualified medical doctor, from the University College Medical School, London and has an MBA from Kellogg Graduate School of Management at Northwestern University.

On This Episode We Discuss:

Differences in metabolism in individuals with Wilson’s disease (WD)

How an accumulation of copper affects the body and body systems that are most affected

How and when WD is diagnosed

Signs that someone may have WD

Pathogenic variants (mutations) that have been identified in the ATP7B gene

The number of people affected by WD

Current/standard treatment recommendations for people with WD and how Cuvrior differs from these treatments

When Cuvrior, now FDA-approved, is officially launching in the US

When it is appropriate for people with WD to start taking Cuvrior

Long-term studies and documented benefits of starting the medication earlier in life


To learn more about Wilson’s disease and find patient information, visit Orphalan's wesbite.

You can also learn more about Cuprior (the name of Cuvrior in Europe with EMA approval) here.


Stay tuned for the next new episode of DNA Today on February 10th! New episodes are released every Friday. In the meantime, you can binge over 220 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Episodes since 2021 are also recorded with video which you can watch

Mark as Played

Advertise With Us

Popular Podcasts

Dateline NBC
Death, Sex & Money

Death, Sex & Money

Anna Sale explores the big questions and hard choices that are often left out of polite conversation.

Stuff You Should Know

Stuff You Should Know

If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.

Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

© 2024 iHeartMedia, Inc.